MedCap AB (publ) (MCAP) - Cash Flow Conversion Efficiency
Based on the latest financial reports, MedCap AB (publ) (MCAP) has a cash flow conversion efficiency ratio of 0.034x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr51.70 Million ≈ $5.56 Million USD) by net assets (Skr1.53 Billion ≈ $164.36 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See how many days can MedCap AB (publ) fund operations to measure how many days the company can operate on defensive assets alone.
MedCap AB (publ) - Cash Flow Conversion Efficiency Trend (2007–2025)
This chart illustrates how MedCap AB (publ)'s cash flow conversion efficiency has evolved over time, based on yearly financial data.
MedCap AB (publ) Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of MedCap AB (publ) ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Rastar Group
SHE:300043
|
0.046x |
|
Lotte Reit Co Ltd
KO:330590
|
N/A |
|
Fujian Nanping Sun Cable Co Ltd
SHE:002300
|
0.077x |
|
HangZhou Radical Energy Saving Technology Co Ltd
SHE:300652
|
0.065x |
|
Shanghai Holystar Information Technology Co. Ltd. A
SHG:688330
|
0.039x |
|
Leshan Electric Power Co Ltd
SHG:600644
|
0.062x |
|
Peakstone Realty Trust
NYSE:PKST
|
0.037x |
|
Liberty Latin America Ltd Class C
NASDAQ:LILAK
|
0.041x |
Annual Cash Flow Conversion Efficiency for MedCap AB (publ) (2007–2025)
The table below shows the annual cash flow conversion efficiency of MedCap AB (publ) from 2007 to 2025. For the full company profile with market capitalisation and key ratios, see MedCap AB (publ) stock valuation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | Skr1.46 Billion ≈ $157.00 Million |
Skr342.70 Million ≈ $36.88 Million |
0.235x | -15.94% |
| 2024-12-31 | Skr1.29 Billion ≈ $138.63 Million |
Skr360.00 Million ≈ $38.74 Million |
0.279x | +25.89% |
| 2023-12-31 | Skr1.03 Billion ≈ $110.53 Million |
Skr228.00 Million ≈ $24.54 Million |
0.222x | +122.94% |
| 2022-12-31 | Skr858.70 Million ≈ $92.41 Million |
Skr85.50 Million ≈ $9.20 Million |
0.100x | -40.27% |
| 2021-12-31 | Skr697.70 Million ≈ $75.08 Million |
Skr116.30 Million ≈ $12.52 Million |
0.167x | -13.19% |
| 2020-12-31 | Skr602.00 Million ≈ $64.78 Million |
Skr115.60 Million ≈ $12.44 Million |
0.192x | -10.50% |
| 2019-12-31 | Skr332.80 Million ≈ $35.81 Million |
Skr71.40 Million ≈ $7.68 Million |
0.215x | -35.16% |
| 2018-12-31 | Skr273.80 Million ≈ $29.47 Million |
Skr90.60 Million ≈ $9.75 Million |
0.331x | +224.47% |
| 2017-12-31 | Skr267.70 Million ≈ $28.81 Million |
Skr27.30 Million ≈ $2.94 Million |
0.102x | -63.41% |
| 2016-12-31 | Skr292.29 Million ≈ $31.45 Million |
Skr81.46 Million ≈ $8.77 Million |
0.279x | +675.70% |
| 2015-12-31 | Skr308.15 Million ≈ $33.16 Million |
Skr-14.92 Million ≈ $-1.61 Million |
-0.048x | -701.63% |
| 2014-12-31 | Skr280.63 Million ≈ $30.20 Million |
Skr2.26 Million ≈ $243.00K |
0.008x | +106.43% |
| 2013-12-31 | Skr221.92 Million ≈ $23.88 Million |
Skr865.00K ≈ $93.09K |
0.004x | -98.02% |
| 2012-12-31 | Skr195.48 Million ≈ $21.04 Million |
Skr38.55 Million ≈ $4.15 Million |
0.197x | +16.49% |
| 2011-12-31 | Skr169.82 Million ≈ $18.28 Million |
Skr28.75 Million ≈ $3.09 Million |
0.169x | -0.54% |
| 2010-12-31 | Skr179.99 Million ≈ $19.37 Million |
Skr30.64 Million ≈ $3.30 Million |
0.170x | +67.04% |
| 2009-12-31 | Skr169.94 Million ≈ $18.29 Million |
Skr17.32 Million ≈ $1.86 Million |
0.102x | +305.17% |
| 2008-12-31 | Skr134.11 Million ≈ $14.43 Million |
Skr3.37 Million ≈ $362.99K |
0.025x | +49.35% |
| 2007-12-31 | Skr127.44 Million ≈ $13.71 Million |
Skr2.15 Million ≈ $230.94K |
0.017x | -- |
About MedCap AB (publ)
MedCap AB (publ) is a private equity firm specializing in investments in secondary direct, later stage, industry consolidation, add-on acquisitions, growth capital, middle market, mature, turnarounds, and buyout. It prefers to invest in Biotechnology; Life sciences; Pharmaceuticals; MedTech including healthcare equipment, software, components, and packaging solutions for life science products; an… Read more